A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) (Sirius)
2026年9月10日 更新者:Windward Bio
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of WIN378 in Participants With Moderate - Severe Chronic Obstructive Pulmonary Disease
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD).
WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms.
The study will test how doses of WIN378 are handled by the body (pharmacokinetics) and assess the safety of the medicine and markers of COPD inflammation in exhaled breath and blood, lung function and COPD control (pharmacodynamics)
研究概览
详细说明
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, and pharmacokinetics of WIN378 in adult participants with moderate - severe chronic obstructive pulmonary disease (COPD).
Participants will continue their standard background COPD therapy.
Eligible participants will receive doses of WIN378 or placebo over a 24-week treatment period.
研究类型
介入性
注册 (估计的)
105
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Juliana Hutchinson, MSc
- 电话号码:+4161 551 75 75
- 邮箱:clinical.trial.enquiry@windwardbio.com
学习地点
-
-
California
-
Los Angeles、California、美国、93534
- 招聘中
- WB Contracted Clinical Research Site
-
-
Florida
-
Miami Lakes、Florida、美国、33014
- 招聘中
- WB Contracted Clinical Research Site
-
-
Massachusetts
-
North Dartmouth、Massachusetts、美国、02747
- 招聘中
- WB Contracted Clinical Research Site
-
-
North Carolina
-
Charlotte、North Carolina、美国、28277
- 招聘中
- WB Contracted Clinical Research Site
-
-
Oregon
-
Medford、Oregon、美国、97504
- 招聘中
- WB Contracted Clinical Research Site
-
-
Pennsylvania
-
DuBois、Pennsylvania、美国、15801
- 招聘中
- WB Contracted Clinical Research Site
-
-
Texas
-
McKinney、Texas、美国、75069
- 招聘中
- WB Contracted Clinical Research Site
-
Waxahachie、Texas、美国、75165
- 招聘中
- WB Contracted Clinical Research Site
-
-
-
-
Buenos Aires
-
Buenos Aires、Buenos Aires、阿根廷、C1023AAB
- 招聘中
- WB Contracted Clinical Research Site
-
Buenos Aires、Buenos Aires、阿根廷、C1028AAP
- 招聘中
- WB Contracted Clinical Research Site
-
Buenos Aires、Buenos Aires、阿根廷、C1122AAK
- 招聘中
- WB Contracted Clinical Research Site
-
Buenos Aires、Buenos Aires、阿根廷、C1425BEN
- 招聘中
- WB Contracted Clinical Research Site
-
Buenos Aires、Buenos Aires、阿根廷、C1425FVH
- 招聘中
- WB Contracted Clinical Research Site
-
Buenos Aires、Buenos Aires、阿根廷、C142ABP
- 招聘中
- WB Contracted Clinical Research Site
-
-
Buenos Aires F.D.
-
Buenos Aires、Buenos Aires F.D.、阿根廷、C1414AIF
- 招聘中
- WB Contracted Clinical Research Site
-
Buenos Aires、Buenos Aires F.D.、阿根廷、C1426ABP
- 招聘中
- WB Contracted Clinical Research Site
-
-
Mendoza Province
-
Buenos Aires、Mendoza Province、阿根廷、M5500AXR
- 招聘中
- WB Contracted Clinical Research Site
-
Mendoza、Mendoza Province、阿根廷、M5500CBA
- 招聘中
- WB Contracted Clinical Research Site
-
-
Santa Fe Province
-
Rosario、Santa Fe Province、阿根廷、S2000KZD
- 招聘中
- WB Contracted Clinical Research Site
-
Rosario、Santa Fe Province、阿根廷、S2013OJN
- 招聘中
- WB Contracted Clinical Research Site
-
Santa Fe、Santa Fe Province、阿根廷、S3000ASF
- 招聘中
- WB Contracted Clinical Research Site
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Adults aged 40 to 80 years
- Post-BD spirometry at screening FEV1/FVC < 0.70 and FEV1 30-80% predicted
- On stable triple inhaled therapy (ICS/LABA/LAMA) for ≥ 3 months
- Former smoker (≥ 10 pack-year history) and abstinence from smoking for ≥ 6 months
- Elevated eosinophil count
- Weight/BMI within allowed range
Exclusion Criteria:
- Clinically significant pulmonary disease other than chronic obstructive pulmonary disease (COPD)
- Clinically significant comorbid medical conditions or infections that, in the investigator's judgment, could affect participant safety or interfere with study conduct
- Clinically significant cardiovascular disease
- Recent respiratory infection or COPD exacerbation
- Exposure to approved or experimental biologic therapies for COPD with less than 5 half-life washout period
- Pregnancy or breastfeeding
- Smoking or diagnosed substance use disorder
- Any condition or circumstance that, in the investigator's opinion, would make participation unsafe or compromise study integrity
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:WIN378 Dose 1
WIN378 SC injections will be administered
|
WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
|
|
实验性的:WIN378 Dose 2
WIN378 SC injections will be administered
|
WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
|
|
实验性的:Placebo
Placebo SC injections will be administered
|
Placebo matching WIN378
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants with Adverse Events (AEs)
大体时间:Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Number of participants with Serious Adverse Events (SAEs)
大体时间:Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in systolic blood pressure (mmHg)
大体时间:Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in diastolic blood pressure (mmHg)
大体时间:Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in pulse rate (beats/minute)
大体时间:Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in respiratory rate (breaths/minute)
大体时间:Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in oxygen saturation (%)
大体时间:Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in body weight (kg)
大体时间:Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in body mass index (kg/m^2)
大体时间:Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in body temperature (°C)
大体时间:Week 0- Week 36
|
Week 0- Week 36
|
|
|
Change from baseline in clinical chemistry laboratory assessments
大体时间:Week 0 - Week 36
|
Clinical chemistry assessments will include serum chemistry (such as sodium, potassium, urea, creatinine) and liver function parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin.
|
Week 0 - Week 36
|
|
Change from baseline in haematology laboratory parameters
大体时间:Week 0 - Week 36
|
Haematology assessments will include haemoglobin, white blood cell count, differential white blood cell counts and platelet count
|
Week 0 - Week 36
|
|
Change from baseline in coagulation laboratory parameters
大体时间:Week 0 - Week 36
|
Coagulation assessments will include activated partial thromboplastin time, international normalised ratio, prothrombin time and fibrinogen
|
Week 0 - Week 36
|
|
Change from baseline in urinalysis parameters
大体时间:Week 0 - Week 36
|
Urinalysis assessments will include protein, pH, blood, glucose and leucocytes
|
Week 0 - Week 36
|
|
Change from baseline in electrocardiogram QT interval
大体时间:Week 0 - Week 36
|
Electrocardiogram assessments will include evaluation of QT interval corrected using Fridericia's formula (QTcF)
|
Week 0 - Week 36
|
|
WIN378 Serum concentration (PK)
大体时间:Week 0 to week 36
|
Week 0 to week 36
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Change from baseline in Blood Eosinophil Count
大体时间:Week 0 to Week 24
|
Week 0 to Week 24
|
|
Change in Fractional Exhaled Nitric Oxide (FeNO)
大体时间:Week 0 to Week 24
|
Week 0 to Week 24
|
|
Change in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
大体时间:Week 0 to Week 24
|
Week 0 to Week 24
|
|
Change in Pre and Post Bronchodilator Forced Vital Capacity (FVC)
大体时间:Week 0 to Week 24
|
Week 0 to Week 24
|
|
Incidence and magnitude of anti-drug antibodies to WIN 378
大体时间:Week 0 to Week 36
|
Week 0 to Week 36
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
调查人员
- 研究主任:Omar Khwaja, MD、Windward Bio
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
有用的网址
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2026年6月2日
初级完成 (估计的)
2027年12月17日
研究完成 (估计的)
2028年1月7日
研究注册日期
首次提交
2026年6月2日
首先提交符合 QC 标准的
2026年6月9日
首次发布 (实际的)
2026年6月12日
研究记录更新
最后更新发布 (实际的)
2026年9月15日
上次提交的符合 QC 标准的更新
2026年9月10日
最后验证
2026年9月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- WB-2102
- U1111-1333-4974 (其他标识符:UTN, World Health Organization (WHO))
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.